Dannaoui Eric, Meletiadis Joseph, Tortorano Anna-Maria, Symoens Françoise, Nolard Nicole, Viviani Maria-Anna, Piens Marie-Antoinette, Lebeau Bernadette, Verweij Paul E, Grillot Renée
Laboratoire de Parasitologie, Mycologie Médicale et Pathologie Exotique, Université Claude Bernard Lyon I, 69373 Lyon Cedex 08, France 2Department of Medical Microbiology, University Medical Center St Radboud, 6500 HB Nijmegen, The Netherlands 3Istituto di Igiene e Medicina Preventiva, Università degli Studi -IRCCS Ospedale Maggiore, 20122 Milan, Italy 4Scientific Institute of Public Health, B-1050 Brussels, Belgium 5Laboratoire Interactions Cellulaires Parasite-Hôte, Université Joseph Fourier Grenoble I, 38706 Grenoble Cedex, France 6European Research Group on Biotypes and Genotypes of Aspergillus fumigatus.
J Med Microbiol. 2004 Feb;53(Pt 2):129-134. doi: 10.1099/jmm.0.05326-0.
Two-hundred sequential Aspergillus fumigatus isolates recovered from 26 immunocompromised patients with invasive aspergillosis or bronchial colonization were tested for their in vitro susceptibility to posaconazole, itraconazole, voriconazole, terbinafine and amphotericin B. Twenty-one patients were treated with amphotericin B and/or itraconazole. Antifungal susceptibilities of the isolates recovered before treatment were not significantly different from those of isolates recovered after the onset of antifungal therapy. The highest MICs were 0.125, 0.5, 0.5, 1 and 1 microg ml(-1) for posaconazole, itraconazole, voriconazole, terbinafine and amphotericin B, respectively. It is concluded that the emergence of resistance in A. fumigatus during antifungal therapy with amphotericin B or itraconazole is an uncommon phenomenon.
从26例患有侵袭性曲霉病或支气管定植的免疫功能低下患者中收集了200株连续的烟曲霉分离株,检测它们对泊沙康唑、伊曲康唑、伏立康唑、特比萘芬和两性霉素B的体外敏感性。21例患者接受了两性霉素B和/或伊曲康唑治疗。治疗前分离株的抗真菌敏感性与抗真菌治疗开始后分离株的敏感性无显著差异。泊沙康唑、伊曲康唑、伏立康唑、特比萘芬和两性霉素B的最高MIC分别为0.125、0.5、0.5、1和lμg/ml。结论是,在使用两性霉素B或伊曲康唑进行抗真菌治疗期间,烟曲霉耐药性的出现是一种罕见现象。